Home » VERTEX ANNOUNCES INITIATION OF DEVELOPMENT PROGRAM FOR AURORA KINASE INHIBITOR
VERTEX ANNOUNCES INITIATION OF DEVELOPMENT PROGRAM FOR AURORA KINASE INHIBITOR
Vertex Pharmaceuticals has begun a Phase II clinical development program for VX-680, an investigational drug candidate targeting Aurora kinase.
The initiation of Phase II development for VX-680 is based on the enrollment of patients with advanced colorectal cancer who may have received up to three prior cancer treatments. The open-label, non-randomized study will enroll approximately 20 patients and is being conducted at major cancer treatment centers in the U.S.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May